Enterprise R&D Portfolio Intelligence
Most portfolio decisions are made with evidence that sits in different teams, different systems and different formats. The decision still has to be made on schedule.
NUVRENZA brings scientific, clinical, regulatory, commercial and financial evidence into one decision view, and expresses each program's changing risk, capital exposure and expected portfolio value in financial terms.
Built for biotechnology, pharmaceutical and life-sciences portfolios. Global deployment.
Start with the size of the challenge
Before looking at any solution, look at the published numbers for R&D portfolios like yours. Read them slowly, and apply them to your own pipeline.
$2.6B
Estimated capitalized cost to bring one new drug to market
DiMasi, Grabowski & Hansen, Journal of Health Economics (2016)
7.9%
Probability that a program entering Phase I reaches approval
BIO, Informa Pharma Intelligence & QLS, Clinical Development Success Rates (2011–2020)
~10 years
Typical development duration from first-in-human to approval
Tufts Center for the Study of Drug Development, published estimates
Below cost of capital
Reported internal rate of return on late-stage pharma R&D in recent years
Deloitte Centre for Health Solutions, Measuring the return from pharmaceutical innovation
Figures above are published external benchmarks, cited for context. They are not NUVRENZA results and not a forecast for your portfolio.
Diagnosis
Not in the failure itself. Failure is part of science. The loss happens in the months between the moment the evidence changed and the moment the decision changed.
A translational result weakens on Tuesday. A regulatory precedent shifts in another region. A competitor reads out earlier than expected. A comparator changes the commercial ceiling. Each of these facts exists somewhere inside your organisation, held by a different team, in a different tool, on a different reporting cycle.
The portfolio review happens quarterly. The evidence changes weekly. So capital continues to flow toward a program at the probability it had last quarter, not the probability it has today.
How much do you estimate one quarter of delayed reallocation costs in your organisation? Take your quarterly R&D spend, and take the share sitting in your two weakest programs. That number is the size of the question.
Quantification
Below is an illustrative portfolio of six programs at a mid-size developer with a $400M annual R&D budget. The structure is what matters: fill in your own figures and the arithmetic behaves the same way.
| Program | Stage | Annual capital | Evidence signal since last review | Capital at risk of misallocation |
|---|---|---|---|---|
| Program A | Phase II | $96M | Biomarker response narrower than modeled | $24M per quarter |
| Program B | Phase III | $150M | Comparator standard of care shifting | $37.5M per quarter |
| Program C | Phase I | $40M | Regulatory precedent now more favourable | Underfunded relative to updated value |
| Program D | Preclinical | $34M | No material change | Stable |
| Program E | Phase II | $50M | Enrolment slower than plan by 5 months | $12.5M per quarter |
| Program F | Phase I | $30M | Manufacturing scale-up risk rising | $7.5M per quarter |
Capital exposed to a decision that is one quarter behind the evidence
$81.5M per quarter — 20.4% of the annual R&D budget
This is an illustrative modeled calculation using a composite portfolio built from published industry benchmarks. It is not a NUVRENZA customer result, not a guarantee, and not a forecast. Substitute your own budget and program mix to produce your own figure.
One solution
NUVRENZA does one thing. It maintains a single, continuously updated financial view of your R&D portfolio, so that every program's changing risk and capital exposure is visible in the same currency as your budget.
Scientific, clinical, regulatory, commercial and financial evidence is brought into one structure. When a piece of evidence changes, the program's probability, capital exposure and expected value change with it — on the day, not at the next planning cycle.
The output is deliberately narrow: a ranked, financially expressed answer to one question. Which program deserves the next unit of capital, and what does it cost to keep funding the others at today's evidence?
Scientific, clinical, regulatory, commercial and financial inputs held in one structure, with each figure traceable to its source and its date.
Every change in probability is translated into capital exposure and expected portfolio value, in the same units your finance function already uses.
Weak signals, shifting probabilities and development delays surface when they appear, so reallocation is a decision rather than a post-mortem.
A single ordered view of programs by expected value per unit of capital, with the trade-off of each alternative allocation stated explicitly.
No second product, no separate analytics initiative, no parallel reporting layer. One view, maintained continuously, in financial language.
Modeled scenarios
NUVRENZA is an enterprise platform for R&D portfolio decisions. The scenarios below are composite, illustrative models built from published industry benchmarks — they are not actual customer results and contain no clinical or patient claims.
Illustrative scenario — mid-size oncology developer
Portfolio reviewed quarterly. A Phase II asset continued at full funding for two cycles after its response signal weakened.
In the modeled view, the same signal changes the program's expected value in week 3 and is visible against the portfolio's capital plan.
Modeled effect: about $19M of quarterly spend redirected two quarters earlier — roughly 7.3% of the annual R&D budget.
Illustrative scenario — rare disease portfolio
Regulatory precedent in a second region improved the case for an early asset, but the portfolio model was refreshed at year end.
In the modeled view, the updated regulatory assumption raises the asset's expected value immediately, ahead of the annual cycle.
Modeled effect: about $11M reallocated toward the strengthened asset three quarters earlier.
Composite example — large-cap pharmaceutical unit
Evidence held across six functions. Portfolio committees worked from summaries prepared weeks earlier.
In the modeled view, one shared evidence layer removes the reconciliation step and the committee reviews current, financially expressed positions.
Modeled effect: 1.8% of annual R&D spend recovered from delayed reallocation — approximately $19.8M.
All three scenarios are modeled and illustrative, built on published industry benchmarks. They are not NUVRENZA customer outcomes, not verified financial returns, and not statements about clinical, patient or regulatory results.
Removing the risk
An enterprise platform should not require an act of faith. The engagement is structured so that the evidence arrives before the commitment does.
01
We begin with your own portfolio and produce your exposure figure using your budget and program mix. You keep the analysis whether or not you continue.
02
If the platform does not produce a defensible, decision-ready portfolio view within 90 days of deployment, the licence fee is returned in full.
03
The annual licence is set as a small fraction of the capital your portfolio places at risk in a single quarter, so the comparison stays straightforward.
Guarantee terms are agreed in the enterprise agreement. Pricing comparisons refer to modeled exposure figures, which are illustrative.
A 45-minute executive briefing, then a quantified view of your portfolio's capital exposure using your figures. No obligation attached to either.
Global engagement. Available in ten languages.
